Real‐World Effectiveness of Rebamipide on Gastritis Symptoms: A Patient‐Focused Approach
Open Access
- 23 August 2025
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (9) , e70327
Abstract
Rebamipide is a gastric mucosal protectant used to relieve gastritis symptoms. Real‐world evidence on the comparative effectiveness of rebamipide monotherapy versus combination therapy with proton‐pump inhibitors (PPIs) in routine clinical settings is limited. This study evaluated the effect of rebamipide in reducing subjective gastrointestinal (GI) symptoms among patients with gastritis symptoms using a patient‐focused approach. This multicenter, observational study enrolled patients aged 19 years and older who were prescribed rebamipide for gastritis symptoms across 81 local clinics and hospitals. Patients received rebamipide twice daily for 2 weeks, with an optional 4‐week extension. GI symptom severity and frequency were collected via patient‐reported outcomes at baseline and posttreatment. Patients were categorized into a rebamipide monotherapy group and a combination therapy group, with inverse probability of treatment weighting (IPTW) applied to adjust for baseline confounding. Statistical analyses included ANCOVA for symptom score changes and chi‐square tests for categorical symptom improvement. Of the 2209 patients included in the analysis, 1946 were in the monotherapy and 263 were in the combination therapy. Both treatment groups showed significant posttreatment reductions in GI symptom scores, and there was no significant difference between the two groups in severity, frequency, and total score before and after IPTW ( p > 0.05). The symptom improvement rate (≥ 50% reduction) was 71.5% in the monotherapy group and 71.4% in the combination therapy group, with no significant difference between the two groups ( p = 0.976). Rebamipide monotherapy provided similar levels of GI symptom relief compared to combination therapy with PPIs in a real‐world clinical setting.Keywords
Funding Information
- Korea Health Industry Development Institute
This publication has 24 references indexed in Scilit:
- The Patient-Reported Outcome (PRO) Consortium: Filling Measurement Gaps for PRO End Points to Support Labeling ClaimsClinical Pharmacology & Therapeutics, 2011
- Anti-inflammatory Effects of Rebamipide According to Helicobacter pylori Status in Patients with Chronic Erosive Gastritis: A Randomized Sucralfate-Controlled Multicenter Trial in China—STARS StudyDigestive Diseases and Sciences, 2008
- Effect of a gastro‐protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: A double‐blind placebo‐controlled study in JapanJournal of Gastroenterology and Hepatology, 2006
- 15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New ApplicationsDigestive Diseases and Sciences, 2005
- Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Beh??et??s DiseaseDrugs in R&D, 2003
- THE EFFECT OF REBAMIPIDE ON CISPLATIN-INDUCED NEPHROTOXICITY IN RATSPharmacological Research, 2000
- Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing.1998
- Effect of rebamipide on liver damage and increased tumor necrosis factor in a rat model of endotoxin shock.1998
- Atrophic Gastritis andHelicobacter pyloriInfection in Patients with Reflux Esophagitis Treated with Omeprazole or FundoplicationNew England Journal of Medicine, 1996
- The Sydney System: A new classification of gastritis. IntroductionJournal of Gastroenterology and Hepatology, 1991